Bruker Daltonics Announces Highest-Performance ESI-Q-q-TOF System.Business Editors/Health/Medical Writers Pittcon 2003 BIOWIRE2K ORLANDO, Fla.--(BUSINESS WIRE)--March 10, 2003 At PittCon 2003, Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) today introduces its BioTOFIII, the next generation of its leading performance floor-standing ESI-TOF and ESI-Q-q-TOF systems, with further significant increases in capabilities. Most often ESI-Q-q-TOF mass spectrometers are utilized in proteomics research, as well as in small molecule structural and accurate mass analysis. The BioTOFIII features new ion optics and new electronics which reaches standard resolution greater than 20,000, twice the standard resolution of other floor-standing ESI-Q-q-TOF systems. The unique and proprietary MultiPass(TM) mode of the BioTOFIII series now even permits resolution greater than 40,000, which is dramatically higher than for any other commercial ESI-TOF system. Frank H. Laukien, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented: "The new BioTOFIII has further extended its performance leadership in the ESI-(Q-q-)TOF (Top Of Form) The beginning of a physical paper form. To position paper in many printers, the printer is turned offline, the forms are aligned properly and the TOF button is pressed. market segment of high-end floor-standing systems, where we expect to gain further marketshare." ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . For more information about Bruker Daltonics, please visit www.bdal.com or www.bdal.de CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion